News

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.
Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...